MAGE family member C3Genealiases: CT7.2 · HCA2 · MAGE-C3 · MAGEC4
Q-omics provides the consensus-scored MAGEC3 profile across patient tissues and cancer cell-line models. MAGEC3 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MAGEC3 is differentially expressed in 7, with the highest sampling consensus in KICH. Additionally, MAGEC3 RNA expression shows 13,059 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, KICH, and TGCT as cancer lineages where MAGEC3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAGEC3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAGEC3 survival associations across molecular data types. MAGEC3 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAGEC3 RNA expression–survival associations across cancer types. High MAGEC3 expression shows unfavorable associations in KIRC, COAD, KIRP, STAD, READ and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for MAGEC3 RNA expression.
This table summarizes MAGEC3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for MAGEC3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAGEC3 shows lower tumor expression in KICH, BRCA and STAD and higher tumor expression in THCA, KIRP and LUAD. The KICH box plot shows higher MAGEC3 RNA expression in normal versus tumor tissue (log2 FC = −0.093, t-test p < 0.001).
This table shows molecular features associated with MAGEC3 in patient tissues and cancer cell lines. In patient samples, MAGEC3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, MAGEC3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in CNS and LARGE_INTESTINE.
